title: Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
abstract: A phase II clinical trial was conducted to examine the clinical and pathologic efficacy and safety of neoadjuvant paclitaxel with or without trastuzumab in women with advanced or metastatic breast cancer. A total of 49 patients with advanced or metastatic breast cancer (clinical stage IIB -IV) were included. Patients with HER2-negative tumors received weekly paclitaxel 80 mg/m2 (days 1, 8, 15) followed by a 1-week break for 4 cycles. Patients with HER2-positive tumors received weekly paclitaxel 80 mg/m2 (days 1, 8, 15) followed by a 1-week break and a trastuzumab 4 mg/kg loading dose, intravenously, followed by 2 mg/kg weekly for 4 cycles. The age of the patients was 51.6 +/- 1.6 years (mean +/- SE) and the size of their tumors was 5.8 +/- 0.4 cm (mean +/- SE). Thirty-two patients had HER2-negative tumors and 17 had HER2-positive tumors. Of 49 patients, 13 (26.5%) had a clinical complete response and 24 (49.0%) had a clinical partial response. Five (10.2%) patients had a pathological complete response (pCR) and three (6.1%) patients had a near pCR in the breast. A total of eight (16.3%) patients had a pCR or near pCR in the breast. The pCR or near pCR rate was 3.1% in the HER2-negative group and 41.2% in the HER2-positive group. With a median follow-up of 28 months (range, 1-45), the 3-year overall survival was 88%. Clinical responders showed a significantly better overall survival than non-responders (p < 0.01). Pathological responders showed a better overall survival than non-responders. There was no significant difference in overall survival between patients with HER2-positive and -negative tumors. In conclusion, combined neoadjuvant weekly paclitaxel and trastuzumab achieved high clinical and pathological response rates for HER2 -overexpressing breast cancers, despite the omission of an anthracycline.
authors.affiliation: Department of Surgery, Gunma University Faculty of Medicine, Gunma, Japan. junhorig@showa.gunma-u.ac.jp
authors.forename: Jun
authors.initials: J
authors.lastname: Horiguchi
authors.forename: Tetsunari
authors.initials: T
authors.lastname: Oyama
authors.forename: Yukio
authors.initials: Y
authors.lastname: Koibuchi
authors.forename: Takao
authors.initials: T
authors.lastname: Yokoe
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takata
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nagaoka
authors.forename: Nana
authors.initials: N
authors.lastname: Rokutanda
authors.forename: Rin
authors.initials: R
authors.lastname: Nagaoka
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Odawara
authors.forename: Mami
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Ayako
authors.initials: A
authors.lastname: Sato
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Iino
authors.forename: Izumi
authors.initials: I
authors.lastname: Takeyoshi